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Abstract
Introduction: Atypical insufficiency fractures of the femur in patients on long-term bisphosphonate therapy have
been well described in recent literature. The majority of cases are associated with minimal or no trauma and occur
in the subtrochanteric or diaphyseal region.
Case presentation: We describe the case of a 76-year-old British Caucasian woman who presented initially to an
emergency department and then to her primary care physician with a long-standing history of bilateral knee pain
after minor trauma. Plain radiographs showed subtle linear areas of sclerosis bilaterally in her proximal tibiae.
Magnetic resonance imaging confirmed the presence of insufficiency fractures in these areas along with her left
distal femur. There are very few reports of atypical insufficiency fractures involving the tibia in patients on long-
term bisphosphonate therapy and this appears to be the only documented bilateral case involving the
metaphyseal regions of the proximal tibia and distal femur.
Conclusion: In addition to existing literature describing atypical fractures in the proximal femur and femoral shaft,
there is a need for increased awareness that these fractures can also occur in other weight-bearing areas of the
skeleton. All clinicians involved in the care of patients taking long-term bisphosphonates need to be aware of the
growing association between new onset lower limb pain and atypical insufficiency fractures.
Introduction
Atypical subtrochanteric and diaphyseal insufficiency
fractures of the femur in association with long-term
bisphosphonate use have been well described in recent
literature [1-6]. The majority of cases are associated
with the most commonly used bisphosphonate alen-
d r o n a t eb u tm a ya l s ob ea s s o c i a t e dw i t ho t h e ra n t i r e -
sorptive agents, corticosteroids and proton pump
inhibitors [4,7].
By causing osteoclast apoptosis, bisphosphonates
decrease bone resorption. This results in increased bone
mineral density and a decreased risk of fracture during
the first five years of administration [8]. Animal studies,
however, demonstrate an accumulation of microdamage
and a lack of effective remodeling within bone after
bisphosphonate use, which has been shown to compro-
mise its biomechanical properties [9,10]. In addition, a
histomorphometric analysis of cancellous bone biopsy
samples in nine patients sustaining spontaneous non-
spinal fractures whilst on bisphosphonate therapy
revealed markedly suppressed bone turnover [4]. It has
also been proposed that long-term bisphosphonate use
may lead to secondary mineralization producing more
brittle bones [11].
We describe a case of atypical bilateral proximal tibial
and unilateral distal femoral insufficiency fractures in an
adult woman who had been receiving tri-monthly intra-
venous pamidronate treatment for approximately six
years.
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A 76-year-old British Caucasian woman presented with a
seven-month history of bilateral knee pain, caused initially
by moving heavy furniture. Her symptoms were exacer-
bated on her left side after striking her knee against a
parked car door five weeks prior to presentation. She
could recall initial mild swelling which settled but no
bruising. Her pain was worse when weight bearing, parti-
cularly on her left leg. An examination of her lower limbs
was unremarkable except for tenderness over the medial
proximal tibias bilaterally. She was initially diagnosed with
cellulitis around her knee by the emergency department,
though the C reactive protein was only mildly elevated at
23, and was prescribed 5 days oral flucloxacillin. Subse-
quent investigations for deep vein thrombosis by her pri-
mary care physician were negative and her symptoms
persisted.
Her relevant medical history included seropositive ero-
sive rheumatoid arthritis for over 30 years, osteomalacia
and osteoporosis. Her relevant drug history included cal-
cium 1200 mg/day, vitamin D3 800 units/day, predniso-
lone 5 mg/day, rabeprazole 20 mg/day, folic acid 10 mg
once a week, intravenous methotrexate 15 mg once a
week, and 30 mg intravenous pamidronate every three
months. She had been taking prednisolone and metho-
trexate for seven years continuously. Blood tests revealed
that her vitamin D, calcium, phosphate, parathyroid hor-
mone and alkaline phosphatase levels were within normal
limits.
Our patient had been treated with oral alendronate for
three years but due to poor tolerance and compliance,
her therapy was changed to intravenous pamidronate
for the following six years. Measurement by dual-energy
X-ray absorptiometry (DXA) was performed at her hip
and lumbar vertebrae three years before bisphosphonate
treatment was commenced and again three years after.
Her T scores at her hip improved from -1.55 to -1.3
and at her lumber vertebrae from -2.86 to -2.5.
Her rheumatologists initially treated the knee pain
with single intra-articular hydrocortisone injections.
Subsequent plain radiographs of both her knees were
reported by the radiologists as having linear areas of
sclerosis involving the medial metaphyseal regions of
both her proximal tibiae. The changes were reported as
more marked on her left side associated with a perios-
teal reaction suggestive of either insufficiency or stress
fractures. No radiographic changes were demonstrated
around her left distal femur (Figure 1).
Our patient was referred to the orthopedic department
where she stated her bilateral knee pains had now sig-
nificantly improved. On examination, she was found to
have a normal gait, mildly swollen knees bilaterally with
tenderness over her left proximal medial tibia and a
good equal range of knee, hip and ankle movement.
Magnetic resonance imaging scans were organized and
demonstrated extra-articular linear signal change on T1,
T2 and short inversion time inversion recovery images
with surrounding marrow edema associated with insuffi-
ciency or stress fractures at the level of the proximal
tibiofibular joint within both tibiae. Her left knee also
demonstrated a fracture line through her distal femur
with associated edema more marked medially and cen-
trally. Her left medial collateral ligament had a slightly
increased signal in keeping with a recent sprain with
marked edema in the suprapatellar fat pad and sur-
rounding soft tissues. There was spotty bone marrow
edema within her right distal femur, but no discrete lin-
ear fracture line was demonstrated (Figure 2).
Her treatment consisted of bilateral knee supports, rest
and protected weight bearing with crutches as tolerated
until her symptoms fully resolved within two months.
Our patient was reviewed one year after presentation
with up-to-date radiographs demonstrating healed frac-
tures around both knees (Figures 3, 4, 5, 6 and 7).
Unfortunately, though her knee symptoms were no
longer an issue, she had sustained a right sided extra-
capsular femoral neck fracture six months previously
after a mechanical fall. This fracture had been treated
operatively with a dynamic hip screw and she was mak-
ing good progress with rehabilitation and recovery,
mobilizing at her last review without any walking aids.
Her rheumatologists had stopped her intravenous pami-
dronate as a caution over the last six months in view of
her multiple insufficiency fractures.
A follow up DXA scan four months previously showed
no significant change in her bone mineral density from
the last result. No other changes were made to her drug
therapy during or after this period.
Figure 1 Anteroposterior radiographs seven months after the
initial symptoms, showing osteosclerotic change with a
periosteal reaction at both medial proximal tibias.
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Long-term bisphosphonate therapy has recently been
associated with atypical proximal metaphyseal and dia-
physeal femoral insufficiency fractures in a number of
case series and reports [1-4,6,7,12-14]. Large rando-
mized trials, however, have not shown a significant
increased risk or a causal relationship [12]. This case
highlights what we believe are atypical bilateral tibial
and unilateral femoral insufficiency fractures occurring
in a patient on long-term bisphosphonate therapy. Pre-
vious reports of atypical tibial insufficiency fractures are
few in number [15,16] and describe fractures of the
tibial diaphysis as opposed to the proximal metaphyseal
fractures seen in this case. Similarities of note between
the cases are that one patient had rheumatoid arthritis
Figure 2 Magnetic resonance imaging coronal short inversion
time inversion recovery images show a linear signal change in
both the proximal tibia and left distal femur with surrounding
reactive change.
Figure 3 Anteroposterior radiographs of both tibiae six
months after diagnosis with resolution of symptoms and
healed fractures.
Figure 4 Anteroposterior radiographs of the left femur six
months after diagnosis with resolution of symptoms and
healed fractures.
Figure 5 Lateral radiograph of the left tibia six months after
diagnosis with resolution of symptoms and healed fractures.
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vitamin D supplements [16]. All the patients were fully
active prior to injury and the fractures were associated
with minimal trauma.
The long-term oral corticosteroids and proton pump
inhibitors which our patient was taking have been
recognized as possible causes for increased fracture risk
[4,14,17]. An increased risk of both vertebral and non-
vertebral fractures has been reported with dosages of
prednisolone or equivalent as low as 2.5 mg to 7.5 mg
daily, and this risk may relate more strongly to daily
rather than to cumulative doses of glucocorticoids [18].
In a large meta-analysis, prior and current use of oral
glucocorticoids increased the risk of any type of fracture,
with no significant difference in relative risk between
men and women [19].
There is also a link between methotrexate and insuffi-
ciency fractures, though in the context of rheumatoid
arthritis this has not been as well established [20]. Stu-
dies have shown increased urinary and fecal excretion of
calcium in methotrexate use, indicating enhanced osteo-
clastic bone resorption, and toxic effects on osteoblasts
resulting in osteopathy. There have also been case
reports of tibia fractures in patients on low dose to
intermediate dose methotrexate therapy [21].
Cases in the literature of atypical fractures in patients
on bisphosphonate therapy include those who were not
taking any of the above mentioned agents and so a direct
causal relationship has yet to be found [2,13].
Insufficiency fractures differ from stress fractures, in that
the bone is abnormal in terms of mineralization, elasticity
and ability to repair from injury, and so normal physiologi-
cal activity can result in fracture [22]. The majority of
documented cases have occurred in patients using alen-
dronate, which is the most commonly used bisphospho-
nate. However, atypical insufficiency fractures have also
been reported amongst users of ibandronate, risedronate,
zoledronate and pamidronate [2,6,7,12,13,16,23]. In a child
with osteogenesis imperfecta, prolonged high dose admin-
istration of intravenous pamidronate has also been asso-
ciated with the development of osteopetrosis [11].
Histomorphometric analysis of bone biopsy samples in
patients taking alendronate has previously revealed severe
suppression of bone turnover [4]. Certainly the absence
of this investigation in our described case is a limitation
when attempting to establish an association between
long-term bisphosphonate therapy and atypical insuffi-
ciency fractures. A bone biopsy could also have helped
differentiate osteomalacia from osteoporosis as the
underlying pathology.
It has been recommended that new onset thigh or hip
pain in patients on long-term bisphosphonate therapy
should be investigated with appropriate plain radio-
graphs [1]. We would extend this recommendation to
bone or joint pain in any weight-bearing area, with or
without a history of low-energy trauma. This is impor-
tant as prodromal pain has been frequently reported in
other series [2] and was also present in our case. It
should be noted, however, that it can take between two
and six weeks from the onset of symptoms to detect any
radiographic changes.
Looser’s zones are associated most frequently with
osteomalacia [24], which could be a cause for these
Figure 6 Lateral radiograph of the right tibia six months after
diagnosis with resolution of symptoms and healed fractures.
Figure 7 Anteroposterior radiographs of the left distal femur
six months after diagnosis with resolution of symptoms.
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often symmetrical with wide transverse lucencies traver-
sing the bone, usually at right angles to the involved
cortex. These changes are present in the plain radio-
graphs but are fairly subtle (Figure 1). Although our
patient takes supplementation for the treatment of
osteomalacia, her blood test results suggest this has
been well controlled for a number of years. The typically
described radiographic findings in previous case series of
atypical insufficiency fractures of the proximal metaphy-
sis and diaphysis of the femur, those of cortical thicken-
ing and a transverse fracture pattern, were also seen in
our case though there was no cortical spiking or beaking
[13,15].
The well-known benefits of bisphosphonate treatment
outweigh the relatively low risk of this rare group of aty-
pical fractures. It also appears that, despite continuing
bisphosphonate therapy, the majority of patients who
sustain a fracture go on to make a full recovery within
the expected timeframe. Further research is needed to
provide guidance as to whether bisphosphonate therapy
should be withheld whilst a patient is recovering from a
fracture. More research is also needed to help identify
any risk factors common to this subgroup of at-risk
patients [14].
Conclusion
The above case highlights that atypical insufficiency
fractures can also occur in other weight-bearing areas of
the skeleton, such as the distal femur and proximal
tibia. A high index of suspicion is recommended for
early diagnosis and prompt treatment amongst all clini-
cians involved in the treatment of patients taking long-
term bisphosphonates. This is particularly important as
such patients are commonly taking other medications
which have also been implicated in increasing the risk
of fracture.
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